立方制药: 第五届董事会第二十一次会议决议公告

Group 1 - The company held its 21st meeting of the 5th Board of Directors on May 12, 2025, with all 7 directors present, confirming compliance with legal and regulatory requirements [1][2] - The Board approved the transfer of 2.2184% equity in Nanjing Mainowei Pharmaceutical Technology Co., Ltd. to Chengdu Yuanhe Yuandian Venture Capital Partnership (Limited Partnership) for a price of RMB 22.183748 million [1][2] - The company conducted a thorough review of the financial and credit status of the counterparty, concluding that they possess sufficient performance capability, and the risk of recovering the payment is controllable [2] Group 2 - The chairman of the company, Ji Junqiu, was authorized to negotiate the specific terms of the equity transfer and sign the relevant documents [2] - The resolution was passed with unanimous support, receiving 7 votes in favor, with no votes against or abstentions [2] - The decision was also reviewed and approved by the Board's Strategic Committee [2]